Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Granules acquires...

    Granules acquires rights for 4 products from US pharma Windlas

    Written by savita thakur thakur Published On 2016-06-10T16:20:00+05:30  |  Updated On 10 Jun 2016 4:20 PM IST
    Granules acquires rights for 4 products from US pharma Windlas

    New Delhi : Pharma firm Granules India said its subsidiary has entered into a product in-licensing pact with US pharma Windlas, LLC to market and distribute four products in the US.


    US pharma Windlas will receive milestone payments and the share of profits from commercial sales.


    In a BSE filing, Granules India said: "Its wholly-owned subsidiary Granules Pharmaceuticals, Inc., (GPI) has acquired the exclusive rights from US pharma Windlas, LLC to market and distribute four products in the USA".


    US pharma Windlas LLC is a joint venture between US pharma Ltd and Windlas Healthcare Pvt Ltd.


    It added: "USpharma Windlas through its subsidiaries holds Abbreviated New Drug Application (ANDA) for Fingolimod, Prasugrel, Dronedarone and Lurasidone. US pharma Windlas believes to be a first applicant to file ANDAs containing paragraph IV certifications for three of these products."


    Granules said it will be responsible for the marketing and distribution of the products in the US, subject to the final approval by the US Food and Drug Administrations (USFDA).


    "Product in-licensing is a strategic monuvere to accelerate our manoveuvre expansion plans in the USA by fostering long term partnerships," Granules India CMD Krishna Prasad Chigurupati said.


    Quoting IMS data, Granules said the four product had annual sales of USD 4.4 billion.


    The company's shares were trading 2.11 per cent higher at Rs 142.70 on BSE.

    Abbreviated New Drug ApplicationANDADronedaroneFingolimodGPIGranulesKrishna Prasad ChigurupatiLurasidonePrasugrelUS Food & Drug AdministrationUSFDAWindlas
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok